Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy

Leukemia & Lymphoma
R L PowlesD Cunningham

Abstract

Interferon (INF) has been incorporated as part of maintenance therapy after high dose treatment in order to make remissions more durable. In this study we have compared peripheral blood stem cell transplant (PBSCT) versus autologous bone marrow transplant (ABMT) with respect to INF tolerance. Thirty nine PBSCT patients have been compared to 37 ABMT patients for INF tolerance. This is followed by a comparison of 15 PBSCT patients versus 21 ABMT patients for engraftment details, response and survival. INF was started at a median of 61 days in the PBSCT and 58 days in the ABMT patients (P = NS). It was well tolerated in both groups without a significant difference in toxicity in the two arms. Engraftment was more rapid in the PBSCT patients with platelet recovery being significantly faster. Response and survival showed a favourable trend for ABMT patients though statistical significance was not reached and the cost of PBSCT was 12% cheaper. We were thus able to conclude that PBSCT grafts were as durable and could tolerate INF just as well as ABMT. Engraftment was more rapid and the procedure of PBSCT was also cheaper. Further studies with a larger group of patients will be required before comments on the efficacy of treatment can ...Continue Reading

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W M GregoryJ S Malpas
Feb 1, 1990·American Journal of Hematology·R AlexanianS Tucker
Jun 2, 1969·JAMA : the Journal of the American Medical Association·R AlexanianH E Wilson
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E SalmonB Barlogie
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D CunninghamJ Malpas
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D CunninghamP J Selby

❮ Previous
Next ❯

Citations

Jan 21, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Theresa HahnPhilip L McCarthy
Oct 2, 2007·Bone Marrow Transplantation·B Sirohi, R Powles

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.